Development of a standard guideline protocol for rodent tobacco smoke inhalation studies task order against in vivo toxicology
Ended Awarded Last action
- Contract number
- HHSF22301002T
- Awardee
-
Lovelace Biomedical And Environmental Research Institute, Inc. UEI N1UBCLRAPNG6
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,373,599
Award facts
- Opportunity
-
- 14223SOL00077 Solicitation number
- In Vivo Toxicology of Tobacco and Related Products Award Notice · Posted Aug 5, 2014
- Contract value 100% obligated
- $1,373,599.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Albuquerque, NM 87108, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,373,599 |
About this award
This is a delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit research organization, to develop a standard guideline protocol for rodent tobacco smoke inhalation studies. The contract has a ceiling value of $1,373,599.00 and is a firm fixed-price task order issued under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract does not have a set-aside designation. LBERI, a subsidiary of Lovelace Biomedical Research Institute, has over 70 years of expertise in inhalation toxicology and has provided preclinical research services to support the development of treatments and cures for respiratory diseases to federal agencies such as the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
Quick answers
Who was awarded contract HHSF22301002T?
HHSF22301002T was awarded to Lovelace Biomedical And Environmental Research Institute, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 6, 2016.
How much is contract HHSF22301002T worth?
The government has obligated $1,373,599 on HHSF22301002T.
Is contract HHSF22301002T an order under another contract?
Yes. HHSF22301002T is a delivery order under HHSF223201510032I, an indefinite delivery contract, on In Vivo Toxicology of Tobacco 2015-2020.
Was contract HHSF22301002T competed?
The extent of competition for HHSF22301002T was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award